MSM/Ms is an inbred mouse strain derived from a Japanese wild mouse, Mus musculus molossinus. In this study, we showed that MSM/Ms mice exhibit dominant resistance when crossed with susceptible FVB/N mice and subjected to the two-stage skin carcinogenesis protocol using 7,12-dimethylbenz(a)anthracene (DMBA)/ 12-O-tetradecanoylphorbol-13-acetate (TPA). A series of F1 backcross mice were generated by crossing p53 +/+ or p53 , enabling us to search for p53-dependent skin tumor modifier genes. Highly significant linkage for papilloma multiplicity was found on chromosomes 6 and 7 and suggestive linkage was found on chromosomes 3, 5 and 12. Furthermore, in order to identify stage-dependent linkage loci we classified tumors into three categories (<2 mm, 2-6 mm and >6 mm), and did linkage analysis. The same locus on chromosome 7 showed strong linkage in groups with <2 mm or 2-6 mm papillomas. No linkage was detected on chromosome 7 to papillomas >6 mm, but a different locus on chromosome 4 showed strong linkage both to papillomas >6 mm and to carcinomas. This locus, which maps near the Cdkn2a/p19
Introduction
The identification of specific genetic variants responsible for increased susceptibility to familial or sporadic cancers has major implications for prediction of individual cancer risk, as well as for development of strategies for prevention or targeted therapy (1, 2) . Mouse models of cancer have been extensively used for the analysis of the genetic basis of cancer susceptibility, and have led to the identification of multiple loci that confer, either alone or in specific combinations, an increased cancer risk (3) (4) (5) (6) (7) (8) .
Inbred strains that were derived recently from mice obtained from the wild are often more resistant to carcinogens and to several types of pathogens compared with the commonly used inbred strains. More specifically, Mus spretus shows dominant resistance to several cancers (e.g. skin cancer (9) , lung cancer (10) and thymic lymphomas (11) ). Exploiting the resistance of M.spretus to the two-stage skin carcinogenesis model involving 7,12-dimethylbenz(a)anthracene (DMBA) initiation and subsequent promotion with 12-O-t etradecanoylphorbol-13-acetate (TPA), 15 skin tumor susceptibility loci, Skts1-15, were identified in an interspecific F1 backcross [(NIH/Ola × M.spretus) × NIH/Ola] (NSP) using quantitative trait locus (QTL) analysis (9, 12) . The Skts1 locus was also identified in Car-R and Car-S crosses (13) , which were generated by the balanced intercross of several inbred strains, including A/J, BALB/C, SJL/J, SWR/J, C57BL/6J, CBA/J, DBA/2 and P/J. In addition to the Skts series, several other skin tumor modifier loci were identified using commonly used inbred strains or wild-derived strains. The Ptch gene was identified as a K5Hras modifier in a C57BL/6J and FVB/N cross (14) . Psl1-4 were identified in a C57BL/6J and DBA cross (15, 16) . Skts-fp 1-3 were identified in a cross between the wild-derived inbred PWK strain and FVB/N mice (17) . Skts-fp 1 was also identified in a study involving a cross between a wild-derived outbred stock of Mus musculus castaneus and FVB/N (18) . The MSM/Ms strain was established from Japanese wild mice, Mus musculus molossinus that were collected in 1978 in Mishima, Japan (19) . Inbreeding of these mice has reached generation N80 at the end of 2011, and they can now be used as a pure inbred strain for genetic studies. MSM/Ms mice show high breeding performance (100-125 N 2 progeny/pair/year) (19) , and have a very low incidence of tumor development (20) (21) (22) (23) (24) . In addition, large numbers of SSLPs (Simple Sequence Length Polymorphisms) and SNPs (Single Nucleotide Polymorphisms) are polymorphic between MSM/Ms and laboratory strains of mice, offering a large repertoire of genetic markers for mapping studies (25, 26) .
In this study, we found that MSM/Ms mice show dominant resistance to chemically induced skin tumor development when crossed with the highly susceptible FVB/N strain (27) . To identify genetic determinants of skin cancer susceptibility, we generated a large backcross population FVB/N × (FVB/N x MSM/Ms) F1 mice, and subjected the animals to DMBA/TPA-induced skin carcinogenesis. Previous studies largely focused on papilloma number as the major phenotype because of the overall low incidence of carcinomas. Because p53 heterozygosity has been shown to be associated with a higher frequency of progression to carcinomas without any effect on papilloma development (28), we used p53 +/-mice to facilitate the identification of loci responsible for tumor progression.
Furthermore, we identified stage-specific papilloma modifiers by classifying papillomas into three categories based on diameter. In other words, papilloma multiplicity in each size category was used as a quantitative trait. In this study, we report the identification of early, mid, late stage papilloma, and carcinoma genetic modifiers, as well as the existence of a novel p53-dependent modifier locus on mouse chromosome 4.
Materials and methods

Mice
All animal experiments were performed under protocols approved by the Niigata University, Experimental Animal Research Facility. FVB/N mice were purchased from Japan Clea. MSM/Ms had been maintained in the Experimental Animal Facility at Niigata University for >20 years. p53 +/-MSM/Ms mice (23) had been maintained on MSM/Ms background for >10 years as well. Female FVB/N mice were crossed with male MSM/Ms and p53 +/-MSM/Ms mice, respectively. Male F1 (FVB/N × MSM/Ms) and p53 +/-F1 (FVB/N × MSM/Ms) were backcrossed to female FVB/N to generate 121 p53 +/+ and 107 p53 +/-F1 backcross mice, respectively. Mice were genotyped using PCR assays as described previously (23) .
Calbiochem. DMBA is used as a carcinogen and TPA as a promoter. 8 MSM/ Ms, 10 FVB/N, 12 F1 (FVB/N × MSM/Ms) hybrids, and 228 F1 backcross mice were treated according to the two-stage carcinogenesis protocol. At 8-10 weeks of age, the backs of mice were carefully shaved with an electric clipper. Two days after shaving, a single dose of DMBA (25 µg per mouse in 200 µl of acetone) was applied to shaved dorsal back skin. One week after initiation, tumors were promoted with TPA (10 µg per mouse in 200 µl of acetone) twice weekly for 20 weeks. Papilloma number and size (mm in diameter) of each papilloma was recorded from 10 weeks up to 20 weeks, and carcinoma development was monitored up to 40 weeks post-TPA treatment.
Classification between papillomas and carcinomas
The majority of papillomas was determined by visual inspection. Papillomas appeared as outgrowths on the dorsal skin of mice. Some of papillomas began to convert to carcinomas by getting more flat on the skin and penetrating deeper into the dermis. They were normally easily distinguishable from one another. However, in some intermediate type tumors, we prepared the paraffin section and confirmed histology.
Histological analysis
Tissues were fixed in 10% buffered formalin, progressively dehydrated through gradients of alcohol, and embedded in paraffin. Samples were sectioned on a microtome at 4 μm thickness, deparaffinized in xylene, rehydrated and then stained with hematoxylin and eosin for histological analysis.
DNA isolation and SNP genotyping
Genomic DNA was isolated using a QIAGEN DNeasy kit from ~5 mm of tail tissue from each mouse. A genome-wide scan was performed in the ABI 7900HT system as described previously (29) . Single nucleotide polymorphisms (SNP) markers spaced every 10-20 Mb were chosen from the Mouse SNP database (http://www.broad.mit.edu/snp/mouse/) and used for genome-wide scanning (Supplementary Table 1 , available at Carcinogenesis Online); I.Miura et al., in preparation). We used 10 additional microsatellite markers for a detailed linkage analysis. The physical location of the markers is based on the data from Ensembl database (http://www.ensembl.org) and the Mouse Genome Database (http://www.informatics.jax.org). PCR was performed as described elsewhere (17) .
Statistical analysis
Phenotype for papilloma and carcinoma susceptibility was scored by the number of papillomas and carcinomas at 20 weeks and at 40 weeks after initiation, respectively. J/qtl, a Java GUI (graphical user interface) for the popular QTL data analysis software R/qtl (30) , was used to analyze phenotype and genotype data from F1 backcross to map QTLs related to susceptibility for chemically induced skin tumors. A permutation test was performed with 10 000 permutations to estimate the empirical threshold value for the mapping.
Results
MSM/Ms is resistant to chemically induced skin tumors
As shown previously, FVB/N mice are highly susceptible to the twostage skin chemical carcinogenesis, developing on average 30.7 ± 0.9 papillomas at 20 weeks after the initiation ( Figure 1A and 1B) . In contrast, none of the 8 MSM/Ms mice developed a single papilloma, indicating that MSM/Ms mice are highly resistant to carcinogen-induced skin carcinogenesis. (Figure 1A and 1B). Similarly, F1 (FVB/N × MSM/Ms) mice were resistant to papilloma development, with 7 of 12 mice having one or two papillomas (0.9 ± 1.2) ( Figure 1B ). Figure 1C shows the size distribution pattern of papillomas of FVB/N mice at the indicated times. In addition, FVB/N mice had a higher incidence and earlier onset of carcinoma compared with MSM/Ms and F1 mice. By 30 weeks after initiation, all FVB/N mice succumbed to their disease while all MSM/Ms and F1 mice were still alive and well ( Figure 1D ). These results demonstrate that MSM/Ms are highly 
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resistant to DMBA/TPA-induced skin carcinogenesis, and that this phenotype is dominant.
DMBA/TPA treatment of p53
+/+ and p53 +/-F1 backcross mice To identify genetic loci that control susceptibility to skin carcinogenesis, we subjected 228 FVB/N × (FVB/N × MSM/Ms) F1 backcross mice, 121 on a p53 +/+ background and 107 on a p53
background, to the DMBA/TPA chemical carcinogenesis protocol and monitored their tumor development for a period of 40 weeks. All mice were genotyped using 107 SNP markers distributed evenly over the genome. For each mouse, we documented the number of papillomas at 20 weeks after initiation as well as the presence of carcinomas at 40 weeks. In addition, papillomas were further categorized into three groups on the basis of size (<2 mm, 2-6 mm and >6 mm in diameter). Figure 2A -E shows the effect of p53 on papilloma and carcinoma development in the F1 backcross mice. Only small difference in 
-test). Error bar is standard deviation (SD). Black bars denote p53
+/+ mice and gray bars denote p53 +/-mice. (D) Percentage of mice bearing at least one carcinoma is plotted. Conversely, carcinoma incidence was enhanced in the presence of p53 knockout allele during the period of the experiment (**P < 0.01, Fisher test at 30 weeks after initiation). Curves get closer at the end point, but P value is still significant (*P < 0.05). (E) Average number of carcinomas per mouse is plotted. Carcinoma number was greatly enhanced in the presence of p53 knockout allele (**P < 0.01, t-test). Closed squares denote p53 +/+ mice and closed triangles denote p53 +/-mice.
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papilloma development is seen between p53 +/+ and p53 +/-F1 backcross mice (Figure 2A-C) . On the other hand, a strong effect on carcinoma development is observed ( Figure 2D and 2E), as described previously (28) .
Highly significant linkage for total papilloma number was found on chromosome 7 When p53
+/+ and p53 +/-mice were combined for analysis, significant linkage was found at 53.6 cM on chromosome 7 (LOD (logarithm of odds) = 6.974) and at 36.0 cM chromosome 6 (LOD = 4.355). Suggestive linkage was found on chromosomes 3, 5 and 12 ( Figure 3A) . We also found significant linkage based on total papilloma number at 53. 6 Linkage analysis on the basis of papilloma size Linkage analysis was also conducted on the basis of papilloma size. Significant linkage for number of papillomas <2 mm occurred at 65.4 cM on chromosome 7 (LOD = 5.063), and suggestive linkage was found on chromosomes 4 and 11, but only in p53 +/+ mice (Supplementary Figure 1C , available at Carcinogenesis Online). No linkage was found in p53 +/-mice based on this category of papilloma size (data not shown). When p53 +/+ and p53 +/-mice were combined for analysis, significant linkage was found at 53.6 cM on chromosome 7 (LOD = 4.869), and suggestive linkage was found on chromosomes 1 and 4 ( Figure 3B) .
Next, linkage analysis was performed using papilloma number of the intermediate size (2-6 mm). In p53 +/+ mice, linkage at 42.0 cM on chromosome 3 (LOD = 3.728) and at 53.6 cM on chromosome 7 (LOD = 3.921) reached statistical significance. Suggestive linkage was detected on chromosomes 6, 11 and 13 (Supplementary Figure 1D , available at Carcinogenesis Online). We did not detect any significant linkage in p53 +/-mice, but suggestive linkage was found on chromosomes 6, 7, 11, 12 and 17 (Supplementary Figure 1E , available at Carcinogenesis Online). When both genotypes were combined, significant linkage was Genetic control of early and late stages of chemically induced skin tumors found at 36.0 cM on chromosome 6 (LOD = 3.787) and at 64.0 cM on chromosome 7 (LOD = 5.314), and suggestive linkage was found on chromosomes 3, 5, 12 and 17 ( Figure 3C ). Taken together, Figure 3A -C shows that the same two markers, D7SNP32 at 53.6 cM and C7.loc64 at 64.0 cM on chromosome 7, defined the linkage peak in all three papilloma size categories (all sizes, <2 mm, 2-6 mm), suggesting that the same gene or set of genes may be involved.
Finally, linkage analysis was conducted on the basis of multiplicity of papillomas >6 mm in diameter. Significant linkage was found only at 44.7 cM on chromosome 4 (LOD = 5.358) in p53 +/+ mice (Supplementary Figure 1F , available at Carcinogenesis Online). In p53 +/-mice, strong linkage was identified at 38.0 cM on chromosome 11 in a region that overlaps with p53, and suggestive linkage was found on chromosome 4 (Supplementary Figure 1G , available at Carcinogenesis Online). Combined results showed almost the same results as that of p53 +/+ mice, but the LOD score of the linkage locus on chromosome 4 increased to almost seven (LOD = 6.992; Figure 3D ). The strong linkage to smaller size (<6 mm) of papillomas was found on chromosome 7; however, this region did not show any linkage to larger size (>6 mm) of papillomas. These results clearly suggest papillomas at early and later stages are under distinct genetic control.
To narrow down the identified linkage regions, precise genotyping was performed with additional 10 informative microsatellite markers on chromosomes 7 and 4. As a result, two peaks were observed on chromosome 7. Highly significant linkage for the papilloma multiplicity was mapped between D7SNP507 and D7SNP513 (interval was 25.2 Mb in size) and between D7SNP6 and D7Mit10 (interval was 10 Mb in size) ( Figure 4A) . A maximum LOD score of 6.974 was mapped at the D7SNP32 and 6.780 at the C7.loc64 individually. Significant linkage for the larger papilloma multiplicity was mapped between D4Mit174 and D4Mit15 (interval was 10.7 Mb in size) ( Figure 4B) . A maximum LOD score of 6.992 was mapped at the D4SNP14.
Genetic screening of carcinoma modifiers
In order to search for loci that might be associated with carcinoma development, linkage analysis on the basis of carcinoma development was carried out. Linkage analysis of p53 +/+ and p53 +/-mice was done separately. As a result, strong linkage (LOD = 4.049) was detected at D4Mit43 at 60.4 cM on chromosome 4 in p53 +/+ F1 backcross mice ( Figure 5A ). The linkage peak at the D4SNP43 is close to the peak at the D4SNP14, which was linked to larger size of papillomas ( Figures 3D and 4B) . This is probably due to the same gene conferring resistance to larger size papillomas and carcinomas. Next, when we performed linkage analysis of p53 +/-F1 backcross mice, surprisingly, the chromosome 4 linkage peak detected in the p53 +/+ group totally disappeared. Instead, linkage was found on chromosome 5 and distal chromosome 11, although these reached only a suggestive significance level ( Figure 5B ). The D11SNP8 on distal chromosome 11 showed linkage to papilloma multiplicity in p53 +/-mice (Supplementary Figure 1B and E, available at Carcinogenesis Online) as well. When both genotypes were combined, suggestive linkage on chromosome 7, and in the middle of chromosome 11 were seen in addition to the significant linkage on chromosomes 4 and suggestive linkage on chromosome 5 (Supplementary Figure 1H , available at Carcinogenesis Online). The third column to the bottom of Table 1 suggests FVB/N/MSM/Ms heterozygous genotype at D5SNP12 in the carcinoma linkage region was associated with carcinoma prone phenotype. FVB/N/FVB/N homozygous genotype was associated with carcinoma-free phenotype. In other words, MSM/Ms allele at D5SNP12 conferred susceptibility to carcinoma development, whereas the FVB/N allele at the same locus conferred resistance.
Allele-specific mutation of Hras and allelic imbalance analysis of distal chromosome 7
The locations of Skts 2 and Hras on distal chromosome 7 are in proximity to the linkage peak at C7.loc 64 in this study ( Figure 4A) . We, therefore, investigated the possibility that the linkage at C7.loc 64 influenced the allele-specificity of Hras gene alterations (31) . Sequence analysis of Hras exon 2 identified a BsmAI restriction site polymorphism between FVB/N and MSM/Ms (Supplementary Figure 2A , available at Carcinogenesis Online). The somatic codon 61 mutation introduces a restriction site for the enzyme XbaI, as reported previously (31) . If the mutation occurs on MSM/Ms allele, this can be detected by the presence of a 91 bp band after double digestion with BsmAI and XbaI (Supplementary Figure 2A , available at Carcinogenesis Online). The majority of papillomas (36/40) produced 91 and 116 bp bands by a single digestion with XbaI (data not shown), indicating the presence of the Hras codon 61 mutation. In the XbaI and BsmAI double digestion, the 91 bp band was retained in 12 papillomas (Supplementary Figure 2B , available at Carcinogenesis Online), indicating that these papillomas had the Hras mutation on the MSM/Ms allele. In the remaining 28 papillomas, the mutation must have occurred on the FVB/N allele, and this difference is statistically significant (P < 0.01, by Fisher test). We next performed allelic imbalance analysis using microsatellite markers on distal chromosome 7 (Supplementary Figure 2C, Figure 2D , available at Carcinogenesis Online). In only one case did the imbalance involved the MSM/Ms allele (P < 0.01 by Fisher test). These results are consistent with a previous study reporting that Skts2 has an influence on the allelic preference of Hras gene alteration (31) .
Discussion
This study shows that MSM/Ms is a dominant resistant strain in the two-stage skin carcinogenesis, when crossed with highly susceptible FVB/N mice. Among the 10 mice in each group, no MSM/Ms developed papillomas, and only a few F1 (FVB/MSM/Ms) hybrid mice developed one or two papillomas. In a population of 228 F1 backcross mice, highly significant QTLs for papilloma development with a maximum LOD score of 7.0 were mapped to chromosomes 7 and 4. A suggestive QTL for carcinoma development was mapped to chromosome 5.
We classified papillomas into three categories based on their diameter, and carried out linkage analysis for each category. Linkage analysis revealed strong linkage at D7SNP32 and C7.loc64 on chromosome 7 to total papilloma number, number of papillomas <2 mm and number of papillomas of 2-6 mm in size. However, these linkage peaks at D7SNP32 and C7.loc64 completely disappeared when the analysis was confined to papillomas >6 mm. These results indicate that a corresponding gene on chromosome 7 functions only at an early papilloma stage, but is not involved at the later stage of papilloma progression, although it is not clear at this stage whether it is involved in initiation. The physical positions of these linkage peaks at D7SNP32 and C7.loc64 are close to Skts1 and Skts2 (9), two of the skin tumor susceptibility loci previously mapped to 30-35 cM and 70-80 cM on chromosome 7, respectively, in a NIH and Mus spretus interspecific backcross. The location of Skts1 was refined by using a large series of congenic lines (32) , moving it more proximally than originally reported (9) . The distance was narrowed to the 4-5 cM region (in the present MGI database, http://www.informatics.jax.org), which is located between D7SNP29 and D7SNP507 in Figure 4A . Two linkage peaks were detected at D7SNP32 and C7.loc64 in our study ( Figure 4A ) that may correspond to Skts1 and Skts2, respectively. The use of congenic lines will enable further refinement of Skts1 or 2, and possibly leading to the identification of the involved genes. The proximal interval including Skts1 region still contains a large number of genes, some of which (e.g. R-ras, Tsg101, Necdin, Atp10a and Genetic control of early and late stages of chemically induced skin tumors Ube3a) are interesting candidate genes for future study. Several important candidate genes are located in the distal interval on chromosome 7, including Pkcb, Hras, etc. Ras genes have been implicated in cancer predisposition in both human and mouse. The initiating event for mouse skin tumors induced by treatment with DMBA involves mutation of the Hras gene at codon 61 (33) . This mutation is detected in 90% of papillomas and carcinomas and is followed by trisomy of chromosome 7, on which Hras is located, leading to preferential duplication of the mutant allele (34) . A previous study also demonstrated the influence of Skts2 on allele-specific mutations in Hras gene (31) . The mouse Hras gene had specific activating mutations in the Mus musculus allele in 90% of DMBA-TPA-induced carcinomas in NIH/Mus spretus crosses. In all cases, tumors with Hras mutations also showed specific imbalance of chromosome 7 markers that favored the chromosome carrying the mutant allele. Frequent mutations were detected on FVB/N allele of the Hras gene, and high frequency of allelic imbalance in favor of FVB/N allele of the Hras gene was also found in our study, as well as in Mus spretus study. These results suggest the linkage peak at C7.loc64 on chromosome 7 showed the same effect on the allele -specificity of Hras mutation as Skts2, suggesting that a common gene might be responsible for Skts2 and the linkage at C7.loc64. In this interval, some other QTLs for susceptibility to other types of tumors have been mapped, including the lung cancer susceptibility loci Sluc8 and Sluc19 (4). Tlsm1 has been mapped as locus conferring susceptibility to lymphoma (35) .
Highly significant linkage to larger papilloma size (>6 mm) was found at D4SNP14 on chromosome 4. This locus did not have any effect on smaller papilloma size or on total number of all size of papillomas. Interestingly, 81.1% of the F1 backcross mice that developed papillomas >6 mm in size were FVB/N allele homozygous at D4SNP14 (Table 1) . When compared with other loci in Table 1 , this ratio of FVB/N homozygous genotype in tumor prone animals is higher, suggesting that FVB/N allele at this locus confers strong susceptibility to increased papilloma growth. On the other hand, 80.0% of papilloma-free mice are FVB/N/MSM/Ms heterozygous at D7SNP32 (fifth column from the top of Table 1 ), suggesting that the MSM/Ms allele at this locus confers strong resistance.
Significant linkage to carcinoma development was found on chromosome 4 in the region associated with late-stage papilloma development. This finding could give us a clue to obtain an answer for a very fundamental question. Skin tumor progression takes place in a number of steps, starting with ras mutation, passing through benign papillomas, some of them progress to carcinoma. However, it is not known whether passage through papilloma to carcinoma is linear, or involves different independent pathways. If the pathway was linear, it would be expected that a locus that confers resistance to papillomas would similarly prevent progression to carcinomas. A strong resistant carcinoma locus on chromosome 4, detected in this study, significantly affects late-stage papillomas, but it does not have any effect on early stage papillomas. These results suggest that a corresponding gene on this locus plays a role in the growth of later stage papilloma instead of papillomagenesis and directly regulates the transition from papilloma to carcinoma. However, the loci detected in this study seem to exert their effects mainly at different stage of tumorigenesis. MSM/Ms allele at the significant resistant papilloma locus on chromosome 7 seems to confer resistance only to papilloma development, but have no effect on carcinoma development. On the other hand, a suggestive carcinoma locus mapped on chromosome 5 has no effect on papilloma development. It seems probably that a very limited number of linear pathway regulating the progression through papilloma to carcinoma are genetically modified by other different independent pathways. Skts7 and Skts-fp1 were mapped at 40-60 cM on chromosome 4 for chemically induced skin papilloma susceptibility by the analysis of NIH and Mus spretus cross, and FVB and PWK cross, respectively (17, 18) . A common gene might be responsible for the susceptibility of these two and our crosses. PWK, Mus spretus and MSM/Ms are wild-derived inbred strains that could share common haplotypes. The haplotype analysis would help to identify a candidate gene in the near future. This region contains many QTLs for susceptibility to other types of tumors (6) . Pctr1 and Pctr2 were mapped as loci for susceptibility to pristane-induced plasmacytoma (36, 37) , and Cdkn2a has been suggested to be a corresponding gene for Pctr1 (38, 39) . Cdkn2a is also a strong candidate gene for Papg1, QTL for progression of urethane-induced lung tumors (40) . This could be a good candidate gene for late-stage papilloma and carcinoma on chromosome 4 in our study. The Cdkn2a locus encodes two separate proteins (Cdkn2a, also known as p16, and p19 Arf ) generated from alternative open reading frames. The p19
Arf protein activates p53 signaling through an interaction with Mdm2 (41) . A previous study demonstrated that more papillomas were induced in p19 Arf -deficient mice, compared with wild-type mice using the DMBA/TPA two-step protocol. Relative to wild-type mice, the size of papillomas was larger in p19 Arf -deficient mice. Malignant conversion of papillomas to squamous cell carcinomas was markedly accelerated in p19 Arf -deficient mice (42) . Our data showing the complete disappearance of the chromosome 4 modifier locus in p53 +/-mice suggest that p19 Arf may play a major role in the transition to large papillomas and carcinomas. It might be expected that reduced gene dosage of p53 reduces the effect of any polymorphism that affects the levels or function of p19
Arf in controlling p53 activity. In this case, the linkage becomes entirely dependent on whether the backcross animal carries the p53 null allele, which would explain the very strong linkage of papilloma size to the p53 locus in the p53 +/-backcross population. Linkage positively regulated in a p53-dependent manner was seen also on chromosomes 3, 11 and 13 as well as on chromosome 4 for total and intermediate size papilloma number. Whereas negatively regulated linkage was seen on chromosomes 12 and 17 (Supplementary Figure 1A , 1B, 1D, E and Supplementary Table 2 , available at Carcinogenesis Online). Another carcinoma locus that is negatively regulated in a p53-dependent manner, conferring susceptibility was found on chromosome 5 in this study. The main reason why we used p53 knockout F1 backcross mice was to increase carcinoma incidence and map significant p53-dependent carcinoma modifiers. But the number of p53 +/-F1 backcross mice treated with DMBA/TPA was relatively small (n = 107), clear linkage positively or negatively regulated in a p53-dependent manner for carcinoma was seen only on chromosomes 4 and 5. Although the linkage on chromosome 5 reached only a suggestive significance level and the region was still quite big, DMBA/TPA treatment using more mice would simply strengthen the linkage and facilitate gene identification in this region.
MSM/Ms is a wild-derived inbred strain that has high genetic diversity in comparison with standard inbred strains (26) . We expected to have a large genetic variation to skin tumor susceptibility between FVB/N and MSM/Ms. We successfully mapped three significant loci on chromosomes 4, 6 and 7 and several suggestive loci. Many tumor susceptibility loci were mapped on the same chromosomal regions where skin tumor susceptibility loci were mapped in this study. Conventional methods, such as haplotype analysis, congenic and recombinant inbred strains, together with bioinformatic analysis based on the accumulated SNP data will facilitate the following gene identification step. 
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